BC
SUPN icon

Brinker Capital’s Supernus Pharmaceuticals SUPN Stock Holding History

Brinker Capital’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-17,727
Closed -$587K – 976
2019
Q2 		$587K Sell
17,727
-1,186
-6% -$40.6K 0.02% 647
2019
Q1 		$663K Buy
18,913
+1,511
+9% +$56.2K 0.03% 593
2018
Q4 		$578K Buy
17,402
+1,379
+9% +$59.3K 0.03% 560
2018
Q3 		$807K Buy
16,023
+1,166
+8% +$57.6K 0.03% 558
2018
Q2 		$889K Buy
14,857
+926
+7% +$48K 0.03% 520
2018
Q1 		$638K Buy
13,931
+640
+5% +$26.7K 0.03% 629
2017
Q4 		$530K Sell
13,291
-584
-4% -$23.1K 0.02% 670
2017
Q3 		$555K Buy
13,875
+1,651
+14% +$71.5K 0.02% 639
2017
Q2 		$527K Buy
12,224
+532
+5% +$18.9K 0.02% 515
2017
Q1 		$366K Buy
11,692
+420
+4% +$11.3K 0.02% 714
2016
Q4 		$285K Buy
+11,272
New +$252K 0.02% 594

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Brinker Capital's SUPN Position: Q3 2019 in Review

Brinker Capital sold out of Supernus Pharmaceuticals (SUPN) in Q3 2019, closing a stake of 17,727 shares — an estimated $587K sold.

Brinker Capital first reported a position in SUPN in Q4 2016 and held it in 11 quarters. The position peaked at $889K in Q2 2018. 243 funds tracked by Wall St. Rank hold SUPN as of Q3 2019.

  • Brinker Capital reported no remaining Supernus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Brinker Capital sold 17,727 Supernus Pharmaceuticals shares in Q3 2019, an estimated $587K.
  • Brinker Capital first reported a position in Supernus Pharmaceuticals in Q4 2016 and held it in 11 quarters.
  • Brinker Capital's Supernus Pharmaceuticals position peaked at $889K in Q2 2018.
  • 243 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2019.

Based on Brinker Capital's 13F filing for Q3 2019, filed 21 Oct 2019.